Aegis Capital Reiterates Buy Rating Following Reports of Positive Statin-Vascepa Combo - Amarin Corp (NASDAQ:AMRN)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

In a report published on Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and a price target of $35 on

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Amarin

(NASDAQ: AMRN) following reports of a positive Statin-Vascepa combo. In the report, Aegis Capital stated, "This morning, Amarin reported positive data from a Phase 1 clinical trial assessing the pharmacokinetic profile of a fixed-dose combination of the firm's flagship drug product, Vascepa (icosapent ethyl) and a statin (in this case, Crestor or rosuvastatin). This data represents a key cornerstone of Amarin's long- term strategy to eke out a solid market position in the cardiovascular space." Amarin closed on Thursday at $6.30.